[email protected] +44 20 8123 2220 (UK) +1 732 587 5005 (US) Contact Us | FAQ |

Eisai Inc - Strategic SWOT Analysis Review

December 2021 | 40 pages | ID: E6C86BCB691EN
GlobalData

US$ 125.00

E-mail Delivery (PDF)

Download PDF Leaflet

Accepted cards
Wire Transfer
Checkout Later
Need Help? Ask a Question
Eisai Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services.

This up-to-the-minute company report will help you to formulate strategies to drive your business by enabling you to understand your partners, customers and competitors better.

Scope
  • Business description – A detailed description of the company’s operations and business divisions.
  • Corporate strategy – GlobalData’s summarization of the company’s business strategy.
  • SWOT analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
  • Company history – Progression of key events associated with the company.
  • Major products and services – A list of major products, services and brands of the company.
  • Key competitors – A list of key competitors to the company.
  • Key employees – A list of the key executives of the company.
  • Executive biographies – A brief summary of the executives’ employment history.
  • Key operational heads – A list of personnel heading key departments/functions.
  • Important locations and subsidiaries – A list of key locations and subsidiaries of the company, including contact details.
Highlights

Eisai Inc (Eisai America), a subsidiary of Eisai Co Ltd, is a healthcare company that discovers, develops and markets pharmaceutical products. The company's major products include Aricept for Alzheimer’s treatment, Aciphex for acid reflux, Akynzeo for nausea and vomiting dring the course of cancer chemotherapy, Aloxi anti-nausea medication injection, Banzel for adjunctive treatment and Panretin for the treatment of skin lesions in AIDS-related Kaposi's sarcoma. The company’s research and development activities focus on therapeutic areas such as neuroscience; cancer, antibody-based programs; vascular, inflammatory and immunological reaction. Eisai America established partnerships and collaborations with global companies such as Pfizer, Janssen Pharmaceutica Inc, and Elan Pharma International Ltd and Elan Pharmaceutical Inc for the development and distribution of drugs. Eisai America is headquartered in New Jersey, the US.

Eisai Inc Key Recent Developments

Nov 30,2021: Eisai and FCNT enter into business alliance aiming to support people living with dementia and to prevent dementia
Nov 01,2021: Eisai Announces Consolidated Financial Report for the Six-month Period Ended September 30, 2021
Sep 13,2021: Data at ESMO Congress 2021 underscore depth of Eisai's oncology pipeline and commitment to cancer care
Aug 30,2021: Eisai Announces New Executive Leadership Team at H3 Biomedicine
Aug 05,2021: Eisai Inc. Announces the Appointment of Dr. Janna Hutz as President of the Eisai Center for Genetics Guided Dementia Discovery

Reasons to Buy
  • Gain key insights into the company for academic or business research purposes. Key elements such as SWOT analysis and corporate strategy are incorporated in the profile to assist your academic or business research needs.
  • Identify potential customers and suppliers with this report’s analysis of the company’s business structure, operations, major products and services and business strategy.
  • Understand and respond to your competitors’ business structure and strategies with GlobalData’s detailed SWOT analysis. In this, the company’s core strengths, weaknesses, opportunities and threats are analyzed, providing you with an up to date objective view of the company.
  • Examine potential investment and acquisition targets with this report’s detailed insight into the company’s strategic, business and operational performance.
Note: Some sections may be missing if data is unavailable for the company.
SECTION 1 - ABOUT THE COMPANY

Eisai Inc - Key Facts
Eisai Inc - Key Employees
Eisai Inc - Key Employee Biographies
Eisai Inc - Major Products and Services
Eisai Inc - History
Eisai Inc - Company Statement
Eisai Inc - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries

SECTION 2 – COMPANY ANALYSIS

Company Overview
Eisai Inc - Business Description
Eisai Inc - Corporate Strategy
Eisai Inc - SWOT Analysis
SWOT Analysis - Overview
Eisai Inc - Strengths
Eisai Inc - Weaknesses
Eisai Inc - Opportunities
Eisai Inc - Threats
Eisai Inc - Key Competitors

SECTION 3 – COMPANY’S LIFESCIENCES FINANCIAL DEALS AND ALLIANCES

Eisai Inc, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
Eisai Inc, Pharmaceuticals & Healthcare, Deals By Type, 2015 to YTD 2021
Eisai Inc, Recent Deals Summary

SECTION 4 – COMPANY’S RECENT DEVELOPMENTS

Nov 30, 2021: Eisai and FCNT enter into business alliance aiming to support people living with dementia and to prevent dementia
Nov 01, 2021: Eisai Announces Consolidated Financial Report for the Six-month Period Ended September 30, 2021
Sep 13, 2021: Data at ESMO Congress 2021 underscore depth of Eisai's oncology pipeline and commitment to cancer care
Aug 30, 2021: Eisai Announces New Executive Leadership Team at H3 Biomedicine
Aug 05, 2021: Eisai Inc. Announces the Appointment of Dr. Janna Hutz as President of the Eisai Center for Genetics Guided Dementia Discovery
Jun 28, 2021: Eisai Announces the Appointment of Dr. Andree Amelsberg as Vice President, U.S. Medical Affairs, Oncology Business Group
Apr 16, 2021: Eisai presents breadth of data across neurology portfolio, including Alzheimer's disease, insomnia and epilepsy
Mar 31, 2021: Eisai and Advocacy leaders team up to launch spot her - an initiative that empowers women to help spot the signs of endometrial cancer
Feb 02, 2021: Eisai and BioLabs partner to create the Eisai Innovation Center BioLabs
Jan 20, 2021: Dr. Richard Woodman appointed Chief Clinical Officer of the Oncology Business Group at Eisai

SECTION 5 – APPENDIX

Methodology
About GlobalData
Contact Us
Disclaimer

LIST OF TABLES

Eisai Inc, Key Facts
Eisai Inc, Key Employees
Eisai Inc, Key Employee Biographies
Eisai Inc, Major Products and Services
Eisai Inc, History
Eisai Inc, Other Locations
Eisai Inc, Subsidiaries
Eisai Inc, Key Competitors
Eisai Inc, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
Eisai Inc, Pharmaceuticals & Healthcare, Deals By Type, 2015 to YTD 2021
Eisai Inc, Recent Deals Summary

LIST OF FIGURES

Eisai Inc, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
Eisai Inc, Pharmaceuticals & Healthcare, Deals by Type, 2015 to YTD 2021


More Publications